



---

## Author Correction: DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B

---

Correction to: *Nature Communications*  
<https://doi.org/10.1038/s41467-025-61420-x>,  
published online 10 July 2025

---

<https://doi.org/10.1038/s41467-026-69394-0>

---

Published online: 06 February 2026

---

 Check for updates

---

Keun-Wook Lee, Devalingam Mahalingam , Byoung Yong Shim , In-Ho Kim, Do-Youn Oh, Hope Uronis, Sun Jin Sym, Mohamad Sonbol, Khaldoun Almhanna, Mohamedtaki A. Tejani, Beodeul Kang, Michael H. Kagey, Melissa Stilian, Calvin Jia , Cynthia A. Sirard , Rachel Altura, Jaffer A. Ajani  & Samuel J. Klempner 

---

In the version of the article initially published, Rachel Altura was missing from the author list and has now been added to the HTML and PDF versions of the article.

**Open Access** This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/>.

© The Author(s) 2026